This is BrainsWay’s global website. The global website is not intended for persons in the United States and includes information on clinical indications that were not cleared by the FDA, which are subject to further US regulatory review for safety and efficacy. BrainsWay D is cleared by the FDA only for patients with MDD who failed to respond to one or more anti-depressants in the current episode, and for patients with OCD as an adjunct treatment.
is ushering in a new era of brain disorder treatment. BrainsWay is continuously seeking to expand its platform, achieving outcomes not thought possible with traditional medical solutions. Through ongoing investment in R&D and in research initiatives ranging from large-scale multicenter trials to personalized medicine studies, BrainsWay represents the next-generation of treatments for depression and OCD.
*See response and remission rates in the MDD and OCD treatment pages
BrainsWay Introduces the First FDA Cleared (De-Novo) Non-invasive Medical Device for the Treatment of OCD.
Major Depressive Disorder is a neuropsychiatric disorder that is expressed in emotional, physiological and behavioral effects.
OF POPULATION IS COVERED BY REIMBURSEMENT
Regain your confidence and learn more about BrainsWay’s groundbreaking technology.
Read what patients share about their experience
Effective H1 coil stimulation for depression requires a dosage of 120% of the resting MT. However, some patients have
Depressed, suicidal patients who failed pharmacologic and brain stimulation protocols have significant hopelessness about future treatment, making a four-week
Literature studies [Bersani et al., 2013] showed the ability to treat different neuropsychiatric disorders using the H1 coil. One of